## **EXHIBIT 3**

```
1
             UNITED STATES DISTRICT COURT
           SOUTHERN DISTRICT OF WEST VIRGINIA
 2
                     AT CHARLESTON
 3
    IN RE: ETHICON, INC, ) MASTER FILE
    REPAIR SYSTEM PRODUCTS, ) NO. 2:12-MD-02327
    LIABILITY LITIGATION
                              ) MDL NO. 2327
 5
 6
                              ) JOSEPH R. GOODWIN
    THIS DOCUMENT RELATES TO ) US DISTRICT JUDGE
    CAROLYN LEWIS, ET AL. V. )
    ETHICON, INC.
    CASE NO. 2:12-CV-04301
 8
 9
             THURSDAY, NOVEMBER 14, 2013
10
11
12
                Deposition of Prof. Dr. Med.
    Uwe Klinge, Volume I, held at the Quellenhoff
13
    Hotel, Monheimsallee 52, 52062 Aachen, Germany,
14
    commencing at 9:01 a.m., on the above date,
15
    before Carrie A. Campbell, Registered
16
    Professional Reporter, Certified Realtime
17
18
    Reporter, Certified Shorthand Reporter,
19
    and Certified Court Reporter.
20
               GOLKOW TECHNOLOGIES, INC.
21
            877.370.3377 ph 917.591.5672 fax
                   deps@golkow.com
22
23
2.4
```

Page 94 Page 96 1 O. 1 A. Yes. There is a draft. Okay. 2 2 But this is the --O. Maybe this is it. 3 3 (Klinge Exhibit 6 marked for Does the next section --Q. 4 4 identification.) A. Compensation is €120,000 and 5 5 then for five years, we got royalties. So **QUESTIONS BY MR. THOMAS:** 6 6 this is the right of 1.5 percent. Let me show you what I've 7 7 1.5 percent of what? marked as Deposition Exhibit Number 6. Q. 8 8 Of the internal -- the internal What is Deposition Exhibit Α. 9 costs, not without the -- so the value of the 9 Number 6? 10 10 meshes they sold in this time period. A. This is a -- so after the 11 11 first -- after this contract stopped in 2005, Okay. For all meshes? Q. 12 12 then we had some discussions how to continue It is not specified here. It 13 is not specified. So later on, I know that our collaboration, our work, and this was 14 it -- that they took the VYPRO, but they took provided in 2009. It was a draft of a 15 as well VYPRO II and ULTRAPROTM. possible contract consulting agreement, how 16 16 to make the further collaboration. O. Okay. So you --17 17 It is not limited to VYPRO. Now, last time we were Α. 18 Q. So you had VYPRO I, VYPRO II together, you testified that the reason why and ULTRAPROTM for which you were paid 19 19 you weren't interested in the contract was 20 20 royalties? because Ethicon would not allow you to work 21 21 with other manufacturers, that's what I A. Yes. 22 22 O. Okav. recall. 23 23 Is that right? A. So this was what I learned from 24 That is -- that is one aspect the letters I got from Ethicon. A. Page 95 Page 97 1 Okay. Is that pretty much the 1 of this. 2 2 substance of this contract? O. Okay. 3 Is there anything else of 3 A. There are several arguments and significance to you in the contract? there are always some pros and some cons, but 4 5 Yeah, I think that is -- and overall, it is just consulting. It is some 6 I'm not -- I'm not allowed to talk to anyone money for some time period where you were 7 asked and this to the prize that you're not else about this agreement. So -- but I was 8 told that Ethicon asked for this agreement allowed to do any other work there. 9 and, therefore, I provided it, but otherwise, 9 O. Okay. 10 10 I would -- I don't hope that I will get in A. And I'm not interested in being 11 conflict by someone else because I open it to a tester for devices or a consulter, just 12 being consulting. I wanted to work on it. a third --13 13 This would mean when I sign You won't. We arranged that. Q. 14 A. Okay. Please --14 this, I may earn some money for some 15 15 consulting activities, but I'm limited in my Q. She takes down every word, and scientific work. And there's no option to she's very good. 16 16 17 17 A. That is so fine. work scientifically in some projects. That 18 18 Now, I understand from your was not included in this and that is my major 19 last deposition, I don't want to replow this 19 criticism to this. 20 20 ground, but sometime in 2005, there was a Exhibit 6 was a document that Q. 21 21 discussion about negotiating a new contract? you produced to us. 22 22 Is that the only draft that you A. Yes. were able to find? 23 23 Q. Did you produce any draft 24 24 contracts to me --I'm sure that in the documents

Page 334 Page 336 1 limited as the other, yeah, you can specific situation. 2 2 think about it, but it doesn't help. MR. THOMAS: Let's stop for the 3 3 QUESTIONS BY MR. THOMAS: day. 4 4 Okay. So if you were asked MR. ANDERSON: Okay. 5 5 today to find out the rate of complications MR. THOMAS: Thank you, Doctor. 6 associated with the risk of the use of mesh 6 (Off the record at 5:57 p.m.) for the treatment of stress urinary 8 incontinence, you don't have anyplace to go, is that what you're telling me? 10 10 MR. ANDERSON: Objection to 11 11 form. 12 12 Answer the question. 13 13 THE WITNESS: The only 14 14 situation I would think that is 15 15 relevant if you have a specific 16 16 patient and she's asking you what do 17 17 you think is the risk there. 18 QUESTIONS BY MR. THOMAS: 18 19 19 So --O. 20 20 So then it depends whether it's A. 21 21 young, whether there's comorbidities and so 22 22 on. And then you can say within the first 23 23 weeks it is a very low risk. That is 24 probably an estimate that you can give. Page 335 Page 337 1 So if a doctor is treating a **CERTIFICATE** woman who has stress urinary incontinence and I, CARRIE A. CAMPBELL, Registered Professional Reporter, Certified Realtime Reporter and Certified Court Reporter, do 3 they're discussing about whether to use mesh to treat the stress urinary incontinence, hereby certify that prior to the commencement of the examination, Uwe Klinge was duly sworn where does the doctor go to understand the by me to testify to the truth, the whole 6 nature of the risks associated with that truth and nothing but the truth.
I DO FURTHER CERTIFY that the 7 mesh? foregoing is a verbatim transcript of the 8 A. He has to go to his own testimony as taken stenographically by and 9 before me at the time, place and on the date experience. So whether -- if he made a hereinbefore set forth, to the best of my 10 follow-up investigation of this patient and ability. 10 11 that is something that has to be required I DO FURTHER CERTIFY that I am 12 more and more, you need some backup from the neither a relative nor employee nor attorney nor counsel of any of the parties to this 13 surgical communities, you have to re -- or action, and that I am neither a relative nor 14 you have to underline the importance of employee of such attorney or counsel, and 13 that I am not financially interested in the 15 follow-up investigations so that you have action. 14 16 your own experience. You have to go to the 15 17 literature, you have to go -- you take the 17 CARRIE A. CAMPBELL, NCRA Registered Professional Reporter 18 information of the companies and that is what 19 you can provide to the patient. And you have 18 Certified Realtime Reporter Missouri Certified Court Reporter #859 20 to think about the long-term -- possible 19 Illinois Certified Shorthand Reporter 21 long-term complications and that, yeah -- and #084-004229 20 Notary Public 22 you have to address some specific risks of 21 Dated: November 26, 2013 23 the patient, that is the discussion about the 22 23 24 possible disadvantages and advantages in a